News
Public · Published
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
InMed Pharmaceuticals, now named Mentari Therapeutics, reported that shareholders approved every item at its November 4, 2026 annual and special meeting. It also completed a share consolidation, exchanging one new common share for every ten old shares.
Published:
Updated:
What happened
InMed Pharmaceuticals, now named Mentari Therapeutics, reported that shareholders approved every item at its November 4, 2026 annual and special meeting. It also completed a share consolidation, exchanging one new common share for every ten old shares.
Confirmed
Global impact / market context
The consolidation reduces the number of shares outstanding per holder while leaving each holder’s proportional ownership broadly unchanged, apart from any treatment of fractional shares. The approved name change may also affect how the company presents itself, but the article gives no operational or financial consequences.
Analyst inference
These are corporate-structure changes, not reported results about drug development, revenue, or cash available. The article confirms broad shareholder participation and approval of all meeting items, but provides no share-price response or detail on the consolidation’s effect on trading or company funding.
Analyst inference
What to watch
- Check the company’s subsequent filings for the full voting breakdown and details of how fractional shares were treated under the completed one-for-ten consolidation. Analyst inference
- Watch for confirmation that the Mentari Therapeutics name is reflected in company filings and trading arrangements; the article announces the name change but gives no implementation details. Analyst inference
- Look for later disclosures on whether the share consolidation changes access to capital or company operations; no such effects are stated in the supplied article. Analyst inference